False positive antibody results against human T‐cell lymphotropic virus in patients with severe acute respiratory syndrome

Tsao, Kuo Chien; Chen, Guang-Wu; Huang, Chung Guei; Huang, Yeu‐Shiang; Lin, Jing; Mok, Chee Keng; Sun, Chien Feng; Shih, Shin Ru

doi:10.1002/jmv.20460

Cited by 14 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The variations verified in the WB test indeterminate results can be partially explained by the different methods used during the period, by the possibility of cross reaction with new varieties of HTLV 12 , cross reaction with other viruses, such as the dengue virus 13 , chickenpox and herpes simplex 14 , severe acute respiratory syndrome virus (SARS) 15 , malaria 14,16 and by the presence of individuals in the initial stages of HTLV infection 17 .…”

Section: Discussionmentioning

confidence: 99%

Decline in prevalence and asymmetric distribution of human T cell lymphotropic virus 1 and 2 in blood donors, State of Minas Gerais, Brazil, 1993 to 2007

Dias-Bastos

Oliveira

Carneiro-Proietti

2010

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Human T cell lymphotropic virus types 1 and 2 (HTLV-1/2) are endemic in Brazil and are screened for in transfusion services since 1993. This study evaluated the evolution of the prevalence of HTLV-1 and 2 in blood donors of the Hemominas Foundation from 1993 to 2007, and its geographical distribution in State of Minas Gerais, Brazil. Methods: The Hemominas Foundation is a centralized blood center in Minas Gerais, Brazil. The sources of data were the Hemominas Foundation Technical Bulletin and files from the centralized serological laboratory. Donors were tested in the period using enzyme linked immuno sorbent assays (ELISA), followed by Western blot, when repeatedly reactive. The data were analyzed by EPIINFO 6.2 and TABWIN 3.5 softwares. Results: The average seroprevalence in the period 1993-2007 was 0.1%. A steady decline occurred from 0.4% in 1993 to below 0.1% in 2002 and later, with a transient peak of 0.5% in 1994. HTLV reactivity distribution was asymmetrical in the state, with regions of higher prevalence, interspersed with low prevalence areas. Comparison of positive and negative donors verified that increasing age was proportional to virus positivity. Odds ratio for age ranged from 1.43 (30 to 39 years-old) to 3.09 (50 to 65 years-old). Women had a greater chance of being positive (OR-1.64), as previously described. Conclusions: Possible explanations for HTLV-1/2 prevalence decline are the exclusion of positive donors from the donor pool, an increase in repeat donors and ELISA test improvement, with reduction in the number of false positive results.

show abstract

Section: Discussionmentioning

confidence: 99%

Decline in prevalence and asymmetric distribution of human T cell lymphotropic virus 1 and 2 in blood donors, State of Minas Gerais, Brazil, 1993 to 2007

Dias-Bastos

Oliveira

Carneiro-Proietti

2010

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…• vaccinations such as influenza [50][51][52][53][54], rabies [55] or HBV [56][57][58] • acute recent infections with other agents [50,59] • allergies [50] • transplantation antigens or autoantibodies [60][61][62] • cross-reactive IgM or IgG antibodies [63,64] • heterophile/polyreactive antibodies [65][66][67] • ventricular assistance devices (non-specific immune activation) [68].…”

Section: Immune Response-relatedmentioning

confidence: 99%

False positive viral marker results in blood donors and their unintended consequences

2018

View full text Add to dashboard Cite

False positive (FP) viral marker results in blood donors continue to pose many challenges. Informing donors of FP results and subsequent deferral can result in stress and anxiety for donors and additional complexity and workload for blood services. Donor management strategies need to balance the requirement to minimise donor anxiety and inconvenience while maintaining sufficiency of supply. Decisions about how and when to inform donors of FP results and determine deferral periods can be difficult as FP results, while often transitory, can take up to several years to resolve. Additional complexities include the interpretation of indeterminate serological confirmatory testing without detectable viral RNA or non-discriminated NAT results with concomitant anti-HBc reactivity - both may be due to FP results, but the former may also represent past infection and the later may represent occult hepatitis B infection. In this review we discuss strategies to minimise indeterminate serological confirmatory results, possible donor deferral policies and the impact on donors when notified of FP results. We also provide some new data from Australia that address the challenge of interpreting non-discriminated NAT results with concomitant anti-HBc reactivity. Ultimately, the challenge is for each blood service to develop appropriate strategies for donor management, taking into account local information and requirements.

show abstract

“…112 SARS-CoV patients' serums falsely cross-react by ELISA and Western blot for human T-lymphotropic virus (HTLV-1 and HTLV-II). 113 Viral cultures are performed in African green monkey Vero E6 cell monolayers. Confirmation is by RT-PCR.…”

Section: Radiologymentioning

confidence: 99%

Severe Acute Respiratory Syndrome (SARS)

Cleri

Ricketti

Vernaleo

2010

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

show abstract

False positive antibody results against human T‐cell lymphotropic virus in patients with severe acute respiratory syndrome

Cited by 14 publications

References 11 publications

Decline in prevalence and asymmetric distribution of human T cell lymphotropic virus 1 and 2 in blood donors, State of Minas Gerais, Brazil, 1993 to 2007

Decline in prevalence and asymmetric distribution of human T cell lymphotropic virus 1 and 2 in blood donors, State of Minas Gerais, Brazil, 1993 to 2007

False positive viral marker results in blood donors and their unintended consequences

Severe Acute Respiratory Syndrome (SARS)

Contact Info

Product

Resources

About